

COVID-19 Vaccines & Administration Codes									
Revised: July 1, 2022									
Submit claim for administration fee with the appropriate vaccine CPT Code (See NOTE tab for additional instructions)									
#	CPT	CPT/HCP/CS Name, Description, Dose	Labeler Name	Drug Name	NDC	Max Allow	Max Units/Day	GAMMIS Effective Date	NOTE
1	91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	Pfizer	PFIZER-BIONTECH COVID-19 VACC 30MCG/0.3ML Suspension	59267-1000-01	\$0.00	1	12/11/2020	Report 91300 with administration codes 0001A, 0002A, 0003A, 0004A
	91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	Pfizer	PFIZER-BIONTECH COVID-19 VACC 30MCG/0.3ML Suspension	59267-1000-02	\$0.00	1	12/11/2020	Report 91300 with administration codes 0001A, 0002A, 0003A, 0004A
	91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	Pfizer	PFIZER-BIONTECH COVID-19 VACC 30MCG/0.3ML Suspension	59267-1000-03	\$0.00	1	12/11/2020	Report 91300 with administration codes 0001A, 0002A, 0003A, 0004A
2	0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose	Pfizer	N/A	N/A	\$40.00	1	12/11/2020	Report 0001A as the first dose administration for 91300
3	0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose	Pfizer	N/A	N/A	\$40.00	1	12/11/2020	Report 0002A as the second dose administration for 91300
4	0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose	Pfizer	N/A	N/A	\$40.00	1	8/12/2021	Report 0003A as the third dose administration for 91300
5	0004A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose	Pfizer	N/A	N/A	\$40.00	1	9/22/2021	Report 0004A as the booster dose administration for 91300
6	91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	Moderna	MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution	80777-0273-10	\$0.00	1	12/18/2020	Report 91301 with administration codes 0011A, 0012A, 0013A
	91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	Moderna	MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution	80777-0273-15	\$0.00	1	12/18/2020	Report 91301 with administration codes 0011A, 0012A, 0013A
	91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	Moderna	MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution	80777-0273-98	\$0.00	1	12/18/2020	Report 91301 with administration codes 0011A, 0012A, 0013A
	91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	Moderna	MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution	80777-0273-99	\$0.00	1	12/18/2020	Report 91301 with administration codes 0011A, 0012A, 0013A
7	0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose	Moderna	N/A	N/A	\$40.00	1	12/18/2020	Report 0011A as the first dose administration for 91301
8	0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; second dose	Moderna	N/A	N/A	\$40.00	1	12/18/2020	Report 0012A as the second dose administration for 91301
9	0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	Moderna	N/A	N/A	\$40.00	1	8/12/2021	Report 0013A as the third dose administration for 91301
10	91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use	Janssen	JANSSEN COVID-19 VACCINE 0.5ML Suspension	59676-0580-05	\$0.00	1	2/27/2021	Report 91303 with administration codes 0031A, 0034A
	91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use	Janssen	JANSSEN COVID-19 VACCINE 0.5ML Suspension	59676-0580-15	\$0.00	1	2/27/2021	Report 91303 with administration codes 0031A,0034A
11	0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage; single dose	Janssen	N/A	N/A	\$40.00	1	12/27/2021	Report 0031A as the single dose administration for 91303

COVID-19 Vaccines & Administration Codes									
Revised: July 1, 2022									
Submit claim for administration fee with the appropriate vaccine CPT Code (See NOTE tab for additional instructions)									
#	CPT	CPT/HCPSC Name, Description, Dose	Labeler Name	Drug Name	NDC	Max Allow	Max Units/Day	GAMMIS Effective Date	NOTE
12	0034A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage,; booster dose	Janssen	N/A	N/A	\$40.00	1	10/20/2021	Report 0034A as the booster dose administration for 91303
13	91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	Pfizer	PFIZER-BIONT COVID-19 VAC-TRIS 30MCG/0.3ML Suspension	59267-1025-01	\$0.00	1	11/1/2021	Report 91305 with administration codes 0051A, 0052A, 0053A, 0054A
	91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	Pfizer	PFIZER-BIONT COVID-19 VAC-TRIS 30MCG/0.3ML Suspension	59267-1025-02	\$0.00	1	11/1/2021	Report 91305 with administration codes 0051A, 0052A, 0053A, 0054A
	91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	Pfizer	PFIZER-BIONT COVID-19 VAC-TRIS 30MCG/0.3ML Solution	59267-1025-03	\$0.00	1	11/1/2021	Report 91305 with administration codes 0051A, 0052A, 0053A, 0054A
	91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	Pfizer	PFIZER-BIONT COVID-19 VAC-TRIS 30MCG/0.3ML Solution	59267-1025-04	\$0.00	1	11/1/2021	Report 91305 with administration codes 0051A, 0052A, 0053A, 0054A
14	0051A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, trissucrose formulation; first dose	Pfizer	N/A	N/A	\$40.00	1	11/1/2021	Report 0051A as the first dose administration for 91305
15	0052A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, trissucrose formulation; second dose	Pfizer	N/A	N/A	\$40.00	1	11/1/2021	Report 0052A as the second dose administration for 91305
16	0053A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, trissucrose formulation; third dose	Pfizer	N/A	N/A	\$40.00	1	11/1/2021	Report 0053A as the third dose administration for 91305
17	0054A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, trissucrose formulation; booster dose	Pfizer	N/A	N/A	\$40.00	1	11/1/2021	Report 0054A as the booster dose administration for 91305
18	91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	Moderna	MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution	80777-0273-10	\$0.00	1	10/20/2021	Report 91306 with administration code 0064A
	91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	Moderna	MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution	80777-0273-15	\$0.00	1	10/20/2021	Report 91306 with administration code 0064A
	91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	Moderna	MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution	80777-0273-98	\$0.00	1	10/20/2021	Report 91306 with administration code 0064A
	91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	Moderna	MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution	80777-0273-99	\$0.00	1	10/20/2021	Report 91306 with administration code 0064A
19	0064A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose	Moderna	N/A	N/A	\$40.00	1	10/20/2021	Report 0064A as the booster dose administration for 91306
20	91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	Pfizer	PFIZER COVID-19 VAC-TRIS 5-11Y 10MCG/0.2ML Suspension	59267-1055-01	\$0.00	1	10/29/2021	Report 91307 with administration codes 0071A, 0072A
	91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	Pfizer	PFIZER COVID-19 VAC-TRIS 5-11Y 10MCG/0.2ML Suspension	59267-1055-02	\$0.00	1	10/29/2021	Report 91307 with administration codes 0071A, 0072A
	91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	Pfizer	PFIZER COVID-19 VAC-TRIS 5-11Y 10MCG/0.2ML Suspension	59267-1055-04	\$0.00	1	10/29/2021	Report 91307 with administration codes 0071A, 0072A
21	0071A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	Pfizer	N/A	N/A	\$40.00	1	10/29/2021	Report 0071A as the first dose administration for 91307

COVID-19 Vaccines & Administration Codes									
Revised: July 1, 2022									
Submit claim for administration fee with the appropriate vaccine CPT Code (See NOTE tab for additional instructions)									
#	CPT	CPT/HCPCS Name, Description, Dose	Labeler Name	Drug Name	NDC	Max Allow	Max Units/Day	GAMMIS Effective Date	NOTE
22	0072A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	Pfizer	N/A	N/A	\$40.00	1	10/29/2021	Report 0072A as the second dose administration for 91307
23	0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	Pfizer	N/A	N/A	\$40.00	1	1/3/2022	Report 0073A as the third dose administration for 91307
24	0074A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS CoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNA LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose	Pfizer	N/A	N/A	\$40.00	1	5/17/2022	Report 0074A as the booster dose administration for 91307
25	91309	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	Moderna	Moderna COVID-19 Vaccine (Blue Cap) 50MCG/0.5ML (Booster)	80777-0275-99 80777-0275-05	\$0.00	1	3/29/2022	Report 91309 with administration code 0094A
26	0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, Booster dose		N/A	N/A	\$40.00		3/29/2022	Report 0094A as the booster dose administration for 91309
27	M0201	Covid-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only covid-19 vaccine administration is performed at the patient's home	N/A	N/A	N/A	\$35.50	1	6/8/2021	Report M0201 with any administration code